- Home
- FTRE vs CRAI Comparison
FTRE vs CRAI Comparison
Compare FTRE & CRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRE
- CRAI
- Stock Information
- Founded
- FTRE 1996
- CRAI 1965
- Country
- FTRE United States
- CRAI United States
- Employees
- FTRE N/A
- CRAI N/A
- Industry
- FTRE Medical Specialities
- CRAI Other Consumer Services
- Sector
- FTRE Health Care
- CRAI Consumer Discretionary
- Exchange
- FTRE Nasdaq
- CRAI Nasdaq
- Market Cap
- FTRE 469.0M
- CRAI N/A
- IPO Year
- FTRE N/A
- CRAI 1998
- Fundamental
- Price
- FTRE $5.95
- CRAI $185.42
- Analyst Decision
- FTRE Hold
- CRAI Buy
- Analyst Count
- FTRE 11
- CRAI 1
- Target Price
- FTRE $18.00
- CRAI $224.00
- AVG Volume (30 Days)
- FTRE 2.3M
- CRAI 60.2K
- Earning Date
- FTRE 05-12-2025
- CRAI 05-01-2025
- Dividend Yield
- FTRE N/A
- CRAI 1.06%
- EPS Growth
- FTRE N/A
- CRAI 21.18
- EPS
- FTRE N/A
- CRAI 7.40
- Revenue
- FTRE $2,696,400,000.00
- CRAI $697,476,000.00
- Revenue This Year
- FTRE N/A
- CRAI $6.59
- Revenue Next Year
- FTRE $3.32
- CRAI $4.80
- P/E Ratio
- FTRE N/A
- CRAI $25.05
- Revenue Growth
- FTRE N/A
- CRAI 8.49
- 52 Week Low
- FTRE $4.77
- CRAI $133.54
- 52 Week High
- FTRE $37.24
- CRAI $214.01
- Technical
- Relative Strength Index (RSI)
- FTRE 43.28
- CRAI 69.40
- Support Level
- FTRE $5.40
- CRAI $164.16
- Resistance Level
- FTRE $6.38
- CRAI $168.74
- Average True Range (ATR)
- FTRE 0.45
- CRAI 6.23
- MACD
- FTRE 0.21
- CRAI 2.84
- Stochastic Oscillator
- FTRE 72.52
- CRAI 90.86
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.